## Nixon & Vanderhve PC.

8TH FLOOR 1100 NORTH GLEBE ROAD ARLINGTON, VIRGINIA 22201-4714 TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100 WRITER'S DIRECT DIAL NUMBER:

(703) 816-4011

### FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

Atty Dkt.:	1579-599	Date:	January 16, 2004	
To: Firm:	Ex	aminer Stucker, USP	J Group: 1648 TO	
Facsimile No.:	(700) 740 7400			
From:	Mary J. Wilson			
Number of Pages (including cover sheet):  ATTACHMENT/S: COURTESY COPY OF LETTER UNDER RULE 312 FILED OCTOBER 27, 2003 W/POSTCARD RECEIPT EVIDENCING THAT FILING. ATTACHED TO THE LETTER UNDER RULE 312 ARE THE PRELIMINARY AMENDMENT DATED AUGUST 21, 2003 AND FACSIMILE RECEIPT EVIDENCING THE FILING OF THAT AMENDMENT				

In re PATENT APPLICATION OF:

HAYNES et al

Serial No.: 09/960,717 - Filed: September 24, 2001

IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND

H2 PEPTIDE

### Dear Examiner Stucker:

Attached is the courtesy copy of the 312 Letter dated October 27, 2003, attachments referenced in that Letter and postcard receipt evidencing the October 27, 2003 filing date. You will note that claim 16 was revised in the Preliminary Amendment to delete the word "noncovalently". That deletion was made to ensure that original claim 17, which depends from claim 16, was properly dependent. In this regard, you will note that claim 17 indicates that gp120, gp41, the ligand and the HR-2 peptide are crosslinked.

(continued)

CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to

By way of background, and to facilitate your review, I direct your attention to the following:

- In the restriction requirement of August 5, 2002, claims 16-18 were indicated as constituting Group II, drawn to an isolated immunogen comprising HR-2 bound to HIV peptide.
- In the Response filed September 5, 2002, Applicants elected Group II, with traverse.
- In the Office Action dated October 11, 2002, the restriction requirement was made final and it was noted that claim 18 (which was does not require the presence of HR-2) was initially included in Group II in error, thus, the October 11, 2002 Action was based solely on a consideration of claims 16 and 17.

I trust the foregoing is helpful but please let me know if you have questions.

Mary J. Wilson

CONFIDENTIALITY NOTE

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RESPONSE UNDER RULE 312** EXPEDITED HANDLING PROCEDURES

In re Patent Application of

Atty Dkt. 1579-599

C# M#

\_\_AYNES et al

Group Art Unit: 1648

Examiner: Stucker, J.

Serial No. 09/960,717

Date: October 27, 2003

Filed:

September 24, 2001 IMMUNOGEN

Title:

Mail Stop Issue Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

LETTER UNDER RULE 312

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other

incorporated by reference and the signature below serves as the digitalization		:4
signature thereon.		
Correspondence Address Indication Form Address		
Fees are attached as calculated below 0 minus highest number  Total effective claims after amendment 0 x \$ 18.00	\$	0.00
DIEVIDUSIY PAIO IO	\$	0.00
Independent claims after amendment 0 minus nignest frames.  Independent claims after amendment 0 minus nignest frames.  O x \$ 86.00  previously paid for 3 (at least 3) = 0 x \$ 86.00  previously paid for 3 (at least 3) = 0 x \$ 86.00	\$	0.00
" proper multiple dependent claims now added for this tarted as as to cover the filing date of this	\$	0.00
etition is hereby made to extend the current due date so as to cover its months) paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months)	\$	0.00
	\$	0.00
Terminal disclaimer enclosed, and \$ 110.00  First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00)  filed		,
First/second submission 2 to the previously unentered , filed  Please enter the previously unentered , filed  Submission attached Subtotal	\$	0.00
	-\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract  Statement filed herewith		
Applicant claims of the second	\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)		0.00
Other: TOTAL FEE ENCLOSED		0.00
to the fee(s) file	ea. or	

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 csimile: (703) 816-4100 :W:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Ref.: 1579-599 In re PATENT APPLICATION OF

Confirmation No. 4196 HAYNES et al

Allowed: October 21, 2003 Serial No.: 09/960,717

Group Art Unit: 1648 Filed: September 24, 2001

Examiner: Stucker, J. For: IMMUNOGEN

October 27, 2003

### LETTER UNDER RULE 312

Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

sir:

Attached is a further copy of an Amendment (and facsimile transmission receipt) filed in the above matter on August 21, 2003. Entry of that Amendment and issuance of a Supplemental Notice of Allowability are requested.

Respectfully submitted,

1,13

MIXON & VANDERHYE, P.C.

Reg. No. 32,955

MJW:tat

1100 North Glebe Road

gth Floor

Arlington, Virginia 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100 NIXON & VANDERHYE PC4 Fax:703-816-4100

### Transmit Conf.Report

Aug 21 2003 17:28

P. 1 Fax/Phone Number	Mode	Start	Time	Page	Result	Note
	NORMAL	21.17:28	2'21'	8	* 0 K	

8TH FLOOR 1100 NORTH GLEBE ROAD ARLINGTON, VIRGINIA 22201-4714

Filed: September 24, 2001

TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100 WRITER'S DIRECT DIAL NUMBER: (703) 816-4011

### FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

	- 10 10 10 10 10 10 10 10 10 10 10 10 10		
Atty Dkt.:	1579-599	Date:	August 21, 2003
To: Firm: Facsimile No.: From: Number of P (IF YOU DO NOT RECEIPLEASE CONTACT US	ages (including co	Mary J.  Over sheet):	8-4242 / (703) 305:3014
ATTACHMENT/S:	official Prelii	MINARY AME	
ATTACHMENT/5.	OF FIGURE 1 115		
MESSAGE:			
In re PATENT APP	LICATION OF:		
HAYNES et al Serial No.: 09/960	,717		

For: IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND HO PEPTIDE PAGE 6/14 \* RCVD AT 1/16/2004 5:11:58 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/0 \* DNIS:7465182 \* CSID:703 816 4100 \* DURATION (mm-ss):02-48

# Nixon & Vanderhye EC.

8TH FLOOR 1100 NORTH GLEBE ROAD ARLINGTON, VIRGINIA 22201-4714 TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100 WRITER'S DIRECT DIAL NUMBER: (703) 816-4011

### FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

Atty Dkt.:	1579-599	Date:	August 21, 2003
To: Firm: Facsimile No.: From: Number of P (IF YOU DO NOT RECEI PLEASE CONTACT US	ages (including	USF (703) 30 Mary J. cover sheet):	, J Group: 1648 PTO 08-4242 / (703) 305 · 30/4 Wilson & ER DIFFICULTIES IN TRANSMISSION,
PLEASE CONTACT CO.			Tabitha A. Trice FACSIMILE OPERATOR
ATTACHMENT/S:	OFFICIAL PRE	LIMINAA I AME	
MESSAGE: In re PATENT APP	PLICATION OF:		
HAYNES et al Serial No.: 09/960 Filed: September For: IMMUNOGE AND H2 PE	24, 2001 EN COMPRISIN	IG AN HIV ENVE	LOPE PROTEIN, A LIGAND

is documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or Agally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED Agally privileged. This information is only intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE Received this faceimile in error, please immediately control to be extended. PAGE 7/14 \* RCVD AT 1/16/2004 5:11:58 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/0 \* DNIS:7465182 \* CSID:703 816 4100 \* DURATION (mm-ss):02-48

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-599

C# M#

HAYNES et al

Group Art Unit: 1648

Serial No. 09/960,717

Examiner: Stucker, J.

Date: August 21, 2003

(itte:

. .ed: September 24, 2001 IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND H2

PEPTIDE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

-	

PRELIMINARY AMENDMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other

signature thereon.				
Correspondence Address Indication Form Attached.				
Fees are attached as calculated below:  Total effective claims after amendment 0 minus highest number  Total effective claims after amendment 0 x \$ 18.00  provingly paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00		
Independent claims after amendment 0 minus nignest number	\$	0.00		
	\$	0.00		
		0.00		
If proper multiple dependent claims now added to the content due date so as to cover the filing date of this  Petition is hereby made to extend the current due date so as to cover the filing date of this  \$ \$ \$ \$				
paper and attachment(s) (\$110.00/111011111)	\$	0.00		
	\$	0.00		
minal disclaimer enclosed, dust of the minal disclaimer enclosed enclosed, dust of the minal disclaimer enclosed enclosed, dust of the minal disclaimer enclosed enclosed enclosed.				
Submission attached Subtotal	\$	0.00		
<del>-</del>	-\$	0.00		
If "small entity," then enter half (1/2) of subtotal and subtract  Statement filed herewith				
F   Applicant claims small chary state	\$	0.00		
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	s	0.00		
Assignment Recording Fee (\$40.00)	•	0.00		
Other: TOTAL FEE ENCLOSED	\$	0.00		
to charge any deficiency, or credit any overpayment, in the fee(s) file	ed, or	v thie		

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 MJW:tat

NIXON & VANDERHYE P.C. By Atty: Mary J. Wilson, Reg. No. 32,955